S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Phase 2 Completed
240 enrolled 14 charts
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase 2 Completed
7 enrolled
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Phase 2 Completed
23 enrolled 10 charts
INNOVATION
Phase 2 Completed
172 enrolled
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
Phase 2 Completed
45 enrolled
ADAPT
Phase 2 Completed
220 enrolled
CRAFT: The NCT-PMO-1602 Phase II Trial
Phase 2 Completed
72 enrolled
TOUCH
Phase 2 Completed
147 enrolled 11 charts
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Phase 2 Completed
673 enrolled 22 charts
TP-II
Phase 2 Completed
257 enrolled
R2D2
Phase 2 Completed
46 enrolled
Keyriched-1
Phase 2 Completed
46 enrolled
Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1
Phase 2 Completed
80 enrolled
Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Phase 2 Completed
32 enrolled 10 charts
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
Phase 2 Completed
40 enrolled 34 charts
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Phase 2 Completed
10 enrolled 12 charts
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
Phase 2 Completed
208 enrolled
GeparX
Phase 2 Completed
780 enrolled
PERTAIN
Phase 2 Completed
258 enrolled 18 charts
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Phase 2 Completed
70 enrolled 11 charts
NA-PHER2
Phase 2 Completed
102 enrolled
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Phase 2 Completed
50 enrolled 13 charts
Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer
Phase 2 Completed
16 enrolled 8 charts
PER-ELISA
Phase 2 Completed
64 enrolled
JOSHUA
Phase 2 Completed
30 enrolled 9 charts
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
Phase 2 Completed
417 enrolled 25 charts
A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer
Phase 2 Completed
129 enrolled 13 charts
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
Phase 2 Completed
225 enrolled 19 charts
VELVET
Phase 2 Completed
213 enrolled 14 charts
A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer
Phase 2 Completed
95 enrolled 17 charts
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Phase 2 Completed
43 enrolled 9 charts
A Study of Pertuzumab in Participants With Metastatic Breast Cancer
Phase 2 Completed
79 enrolled 23 charts
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy
Phase 2 Completed
51 enrolled 9 charts
Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
Phase 2 Completed
42 enrolled 10 charts
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2 Completed
131 enrolled 11 charts
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Phase 2 Completed
149 enrolled 20 charts
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Phase 2 Completed
51 enrolled 27 charts
PENGUIN
Phase 2 Completed
41 enrolled 10 charts
Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab
Phase 2 Completed
37 enrolled